Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Darifenacin hydrobromide (UK-88525) 是一种选择性 M3 蕈毒碱受体拮抗剂,pKi 为 8.9。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 255 | 现货 | ||
50 mg | ¥ 395 | 现货 | ||
100 mg | ¥ 497 | 现货 | ||
500 mg | ¥ 1,223 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 274 | 现货 |
产品描述 | Darifenacin hydrobromide (UK-88525) is a selective muscarinic receptor antagonist used to treat urinary incontinence and overactive bladder syndrome. |
靶点活性 | M3 mAChR:8.9(pKi) |
体外活性 | Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat. [1] Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6?μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6. [2] |
体内活性 | Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55%. [1] Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers. [3] Darifenacin (7.5 mg and 15 mg, daily) reduces the number of incontinence episodes per week from baseline by 67.7% and 72.8% respectively compared with 55.9% with placebo in patients with overactive bladder (OAB). Darifenacin (7.5 mg and 15 mg, daily) also shows significantly superior to placebo for improvements in micturition frequency, bladder capacity, frequency of urgency, severity of urgency and number of incontinence episodes leading to a change in clothing or pads in patients with overactive bladder (OAB). [4] |
别名 | 氢溴酸达非那新, Darifenacin HBr, UK-88525 |
分子量 | 505.45 |
分子式 | C28H31BrN2O2 |
CAS No. | 133099-07-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (184 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9784 mL | 9.8922 mL | 19.7844 mL | 49.4609 mL |
5 mM | 0.3957 mL | 1.9784 mL | 3.9569 mL | 9.8922 mL | |
10 mM | 0.1978 mL | 0.9892 mL | 1.9784 mL | 4.9461 mL | |
20 mM | 0.0989 mL | 0.4946 mL | 0.9892 mL | 2.473 mL | |
50 mM | 0.0396 mL | 0.1978 mL | 0.3957 mL | 0.9892 mL | |
100 mM | 0.0198 mL | 0.0989 mL | 0.1978 mL | 0.4946 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Darifenacin hydrobromide 133099-07-7 Neuroscience AChR 氢溴酸达非那新 Darifenacin Hydrobromide Darifenacin Darifenacin HBr Muscarinic acetylcholine receptor UK-88525 UK88525 inhibit mAChR UK 88525 Inhibitor inhibitor